rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A combination of encorafenib, cetuximab, and binimetinib resulted in significantly longer overall survival and a higher response rate than standard therapy in patients with metastatic colorectal cancer with the <i>BRAF</i> V600E mutation.
|
31566309 |
2019 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer.
|
31840683 |
2019 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Patients with BRAF (v-Raf murine sarcoma viral oncogene homolog B) V600E-mutated metastatic colorectal cancer (mCRC) have a poor prognosis.
|
30662270 |
2019 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Promising clinical trials using combination therapies that inhibit the mitogen-activated protein kinase (MAPK) pathway and alternative active pathways have demonstrated major advances for patients with BRAF V600E-mutated mCRC.
|
31219603 |
2019 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Approximately 10% of metastatic colorectal cancer (mCRC) cases will harbor the BRAF p.V600E mutation (BRAF-mCRC) and have been associated with a poor prognosis.
|
30638691 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Approximately 10% of metastatic colorectal cancer (mCRC) cases will harbor the BRAF p.V600E mutation (BRAF-mCRC) and have been associated with a poor prognosis.
|
30638691 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A combination of encorafenib, cetuximab, and binimetinib resulted in significantly longer overall survival and a higher response rate than standard therapy in patients with metastatic colorectal cancer with the <i>BRAF</i> V600E mutation.
|
31566309 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer.
|
31840683 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Patients with BRAF (v-Raf murine sarcoma viral oncogene homolog B) V600E-mutated metastatic colorectal cancer (mCRC) have a poor prognosis.
|
30662270 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Promising clinical trials using combination therapies that inhibit the mitogen-activated protein kinase (MAPK) pathway and alternative active pathways have demonstrated major advances for patients with BRAF V600E-mutated mCRC.
|
31219603 |
2019 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.
|
28972961 |
2017 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Of 63 patients with BRAF V600E-mutated mCRC and sufficient clinical data, 27 (42.9%) had right-sided colon tumors, 19 (30.2%) had left-sided colon tumors, and 17 (26.9%) had rectal tumors; 26 (41.3%) had peritoneal metastases, and 50 (79.4%) had distant lymph node metastases.
|
29037218 |
2017 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Of 63 patients with BRAF V600E-mutated mCRC and sufficient clinical data, 27 (42.9%) had right-sided colon tumors, 19 (30.2%) had left-sided colon tumors, and 17 (26.9%) had rectal tumors; 26 (41.3%) had peritoneal metastases, and 50 (79.4%) had distant lymph node metastases.
|
29037218 |
2017 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.
|
28972961 |
2017 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location.
|
27956538 |
2016 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features.
|
27261210 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features.
|
27261210 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location.
|
27956538 |
2016 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Metastatic colorectal cancer (mCRC) that harbours a BRAF V600E mutation (BRAF MT) is associated with poorer outcomes.
|
25989278 |
2015 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These data suggest that combined therapy with RAF and EGFR inhibitors could be an effective strategy for treating BRAF V600E mCRC.
|
25589621 |
2015 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF codon 594 or 596 mutated mCRCs are different from BRAF V600E ones in terms of molecular features, pathological characteristics and clinical outcome.
|
26153495 |
2015 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutation is seen in 5% to 8% of patients with metastatic colorectal cancer (CRC) and is associated with poor prognosis.
|
26460303 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These data suggest that combined therapy with RAF and EGFR inhibitors could be an effective strategy for treating BRAF V600E mCRC.
|
25589621 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutation is seen in 5% to 8% of patients with metastatic colorectal cancer (CRC) and is associated with poor prognosis.
|
26460303 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Metastatic colorectal cancer (mCRC) that harbours a BRAF V600E mutation (BRAF MT) is associated with poorer outcomes.
|
25989278 |
2015 |